CXC-Chemokine Receptor 4 Antagonist AMD3100 Promotes Cardiac Functional Recovery After Ischemia/Reperfusion Injury via Endothelial Nitric Oxide Synthase–Dependent Mechanism
- 1 January 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 127 (1), 63-73
- https://doi.org/10.1161/circulationaha.112.099242
Abstract
Background—: CXC-chemokine receptor 4 (CXCR4) regulates the retention of stem/progenitor cells in the bone marrow (BM), and the CXCR4 antagonist AMD3100 improves recovery from coronary ligation injury by mobilizing stem/progenitor cells from the BM to the peripheral blood. Thus, we investigated whether AMD3100 also improves recovery from ischemia/reperfusion injury, which more closely mimics myocardial infarction in patients, because blood flow is only temporarily obstructed. Methods and Results—: Mice were treated with single subcutaneous injections of AMD3100 (5 mg/kg) or saline after ischemia/reperfusion injury. Three days later, histological measurements of the ratio of infarct area to area at risk were smaller in AMD3100-treated mice than in mice administered saline, and echocardiographic measurements of left ventricular function were greater in the AMD3100-treated mice at week 4. CXCR4 + cells were mobilized for just 1 day in both groups, but the mobilization of sca1 + /flk1 + cells endured for 7 days in AMD3100-treated mice compared with just 1 day in the saline-treated mice. AMD3100 upregulated BM levels of endothelial nitric oxide synthase (eNOS) and 2 targets of eNOS signaling, matrix metalloproteinase-9 and soluble Kit ligand. Furthermore, the loss of BM eNOS expression abolished the benefit of AMD3100 on sca1 + /flk1 + cell mobilization without altering the mobilization of CXCR4 + cells, and the cardioprotective effects of AMD3100 were retained in eNOS-knockout mice that had been transplanted with BM from wild-type mice but not in wild-type mice with eNOS-knockout BM. Conclusions—: AMD3100 prolongs BM progenitor mobilization and improves recovery from ischemia/reperfusion injury, and these benefits appear to occur through a previously unidentified link between AMD3100 and BM eNOS expression.Keywords
This publication has 39 references indexed in Scilit:
- Endothelial Nitric Oxide Synthase Overexpression Restores the Efficiency of Bone Marrow Mononuclear Cell-Based TherapyThe American Journal of Pathology, 2011
- CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarctionProceedings of the National Academy of Sciences of the United States of America, 2010
- Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardiumJournal of Molecular and Cellular Cardiology, 2008
- Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heartThe Journal of Experimental Medicine, 2007
- Bone Marrow-Derived CXCR4+ Cells Mobilized by Macrophage Colony-Stimulating Factor Participate in the Reduction of Infarct Area and Improvement of Cardiac Remodeling after Myocardial Infarction in MiceThe American Journal of Pathology, 2007
- Endothelial Progenitor Cells Are Rapidly Recruited to Myocardium and Mediate Protective Effect of Ischemic Preconditioning via “Imported” Nitric Oxide Synthase ActivityCirculation, 2005
- Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonistBlood, 2003
- The Chemokine SDF-1 Is a Chemoattractant for Human CD34+ Hematopoietic Progenitor Cells and Provides a New Mechanism to Explain the Mobilization of CD34+ Progenitors to Peripheral BloodThe Journal of Experimental Medicine, 1997
- Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P.JCI Insight, 1994
- Nitric Oxide Promotes DNA Synthesis and Cyclic GMP Formation in Endothelial Cells from Postcapillary VenulesBiochemical and Biophysical Research Communications, 1993